← Leaderboards
John K. Buolamwini
University Of Tennessee Health Sci Ctr
$5,902,126
Attributed
$6,989,626
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,989,626 · 15
By mechanism
R21$2,044,494 · 5
RF1$1,950,000 · 1
R01$1,089,316 · 1
K01$749,200 · 1
R03$585,833 · 4
R15$345,783 · 2
Top collaborators
- Grace Stutzmann1 shared
- Grace E. Stutzmann1 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsSuccessAnalogPreventCellsNucleosidesToxic EffectLeadInhibitor/AntagonistPropertyChemical SynthesisInterdisciplinary ApproachPharmaceutical ChemistryNucleoside TransporterTransport InhibitorBiologicalMolecularBaseMembrane Transport ProteinsUptakeDesignBiochemicalIn VitroHighly Active Antiretroviral Therapy
Grant awards (34)
Developing Selective Inhibitors and Probes for Concentrative Nucleoside Transporters$176,196
R21 · FY2025 · AI · contact PI
Developing Selective Inhibitors and Probes for Concentrative Nucleoside Transporters$207,131
R21 · FY2024 · AI · contact PI
Studies on Probenecid Prodrugs that Protect against Mitochondrial Toxicity of Tenofovir$195,000
R21 · FY2023 · AI · contact PI
Studies on Probenecid Prodrugs that Protect against Mitochondrial Toxicity of Tenofovir$234,000
R21 · FY2022 · AI · contact PI
Optimization of Novel Ryanodine Receptor Modulatory Compounds for Alzheimer's Disease$225,000
R41 · FY2018 · AG
Novel Drug Discovery for AD Targeting Ryanodine Calcium Channels$1,950,000
RF1 · FY2016 · AG
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside$244,241
R01 · FY2015 · GM · contact PI
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside$171,402
R01 · FY2014 · GM · contact PI
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside$123,131
R01 · FY2014 · GM · contact PI
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside$264,295
R01 · FY2013 · GM · contact PI
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside$286,247
R01 · FY2012 · GM · contact PI
Inhibitors of the ENT4 Adenosine Transporter for Cardioprotection$185,000
R21 · FY2010 · HL · contact PI
Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV Agents$183,394
R21 · FY2010 · AI · contact PI
Mechanism of Chemoprevention Action and SAR of a Tetrahydroisoquinoline Riboside$74,000
R03 · FY2010 · CA · contact PI
Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV Agents$244,561
R21 · FY2009 · AI · contact PI
Inhibitors of the ENT4 Adenosine Transporter for Cardioprotection$222,000
R21 · FY2009 · HL · contact PI
Mechanism of Chemoprevention Action and SAR of a Tetrahydroisoquinoline Riboside$73,833
R03 · FY2009 · CA · contact PI
Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents$73,000
R03 · FY2009 · AI · contact PI
Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents$73,000
R03 · FY2008 · AI · contact PI
DEVELOPMENT OF NOVEL CHEMOPRVENTIVE AGENTS$73,000
R03 · FY2008 · CA · contact PI
DEVELOPMENT OF NOVEL CHEMOPRVENTIVE AGENTS$73,000
R03 · FY2007 · CA · contact PI
Nucleoside Transporters In HAART Mitochondrial Toxicity$178,212
R21 · FY2006 · AI · contact PI
Nucleoside Transporters In HAART Mitochondrial Toxicity$219,000
R21 · FY2005 · AI
NUCLEOSIDE TRANSPORT INHIBITORS FOR CANCER PREVENTION$73,000
R03 · FY2005 · CA
NBMPR-BINDING SITE OF THE HUMAN ES ADENOSINE TRANSPORTER$149,840
K01 · FY2004 · HL
NUCLEOSIDE TRANSPORT INHIBITORS FOR CANCER PREVENTION$73,000
R03 · FY2004 · CA
NUCLEOSIDE TRANSPORTERS AS CHEMOPREVENTION TARGETS$31,478
R15 · FY2004 · CA
Novel Agents Targeted To p53-Mdm2 Pathways$28,305
R15 · FY2004 · CA
NBMPR-BINDING SITE OF THE HUMAN ES ADENOSINE TRANSPORTER$149,840
K01 · FY2003 · HL
NUCLEOSIDE TRANSPORTERS AS CHEMOPREVENTION TARGETS$143,000
R15 · FY2003 · CA
Novel Agents Targeted To p53-Mdm2 Pathways$143,000
R15 · FY2003 · CA
NBMPR-BINDING SITE OF THE HUMAN ES ADENOSINE TRANSPORTER$149,840
K01 · FY2002 · HL
NBMPR-BINDING SITE OF THE HUMAN ES ADENOSINE TRANSPORTER$149,840
K01 · FY2001 · HL
NBMPR-BINDING SITE OF THE HUMAN ES ADENOSINE TRANSPORTER$149,840
K01 · FY2000 · HL